GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Cyclically Adjusted PB Ratio

Soligenix (Soligenix) Cyclically Adjusted PB Ratio : 0.22 (As of Jun. 09, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Soligenix Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Soligenix's current share price is $3.78. Soligenix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $17.05. Soligenix's Cyclically Adjusted PB Ratio for today is 0.22.

The historical rank and industry rank for Soligenix's Cyclically Adjusted PB Ratio or its related term are showing as below:

SNGX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.22   Med: 1.43   Max: 21.98
Current: 0.22

During the past years, Soligenix's highest Cyclically Adjusted PB Ratio was 21.98. The lowest was 0.22. And the median was 1.43.

SNGX's Cyclically Adjusted PB Ratio is ranked better than
80.48% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs SNGX: 0.22

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Soligenix's adjusted book value per share data for the three months ended in Mar. 2024 was $1.168. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $17.05 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Soligenix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Soligenix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Cyclically Adjusted PB Ratio Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 1.18 1.31 15.83 19.93

Soligenix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 19.93 0.56

Competitive Comparison of Soligenix's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Soligenix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Soligenix's Cyclically Adjusted PB Ratio falls into.



Soligenix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Soligenix's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.78/17.05
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soligenix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Soligenix's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.168/131.7762*131.7762
=1.168

Current CPI (Mar. 2024) = 131.7762.

Soligenix Quarterly Data

Book Value per Share CPI Adj_Book
201406 -559.904 100.560 -733.715
201409 -465.288 100.428 -610.527
201412 -15.446 99.070 -20.545
201503 -172.917 99.621 -228.730
201506 -320.291 100.684 -419.200
201509 -41.312 100.392 -54.227
201512 -1.381 99.792 -1.824
201603 -80.337 100.470 -105.369
201606 2.484 101.688 3.219
201609 138.747 101.861 179.495
201612 324.572 101.863 419.887
201703 255.088 102.862 326.792
201706 152.956 103.349 195.028
201709 127.431 104.136 161.255
201712 173.722 104.011 220.096
201803 111.752 105.290 139.864
201806 71.942 106.317 89.170
201809 125.787 106.507 155.631
201812 85.233 105.998 105.961
201903 69.693 107.251 85.630
201906 46.562 108.070 56.776
201909 31.417 108.329 38.217
201912 16.075 108.420 19.538
202003 32.725 108.902 39.599
202006 50.625 108.767 61.334
202009 59.545 109.815 71.453
202012 29.308 109.897 35.143
202103 103.862 111.754 122.470
202106 93.395 114.631 107.364
202109 84.755 115.734 96.503
202112 60.026 117.630 67.245
202203 36.786 121.301 39.963
202206 23.447 125.017 24.715
202209 5.746 125.227 6.047
202212 -13.593 125.222 -14.304
202303 -18.497 127.348 -19.140
202306 9.429 128.729 9.652
202309 6.507 129.860 6.603
202312 3.888 129.419 3.959
202403 1.168 131.776 1.168

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Soligenix  (NAS:SNGX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Soligenix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Soligenix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (Soligenix) Business Description

Industry
Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
Timothy R. Cote director 3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube officer: CMO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber director, officer: Chairman, CEO and President 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino officer: Chief Financial Officer 100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini officer: CSO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson director, 10 percent owner 3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza other: Former 10% Owner VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144